Pfizer Experiences Revision in Stock Evaluation Amid Market Fluctuations Pfizer, a leading name in the pharmaceuticals and drugs sector, has recently undergone a revision in its stock evaluation. This adjustment comes in light of the company's current market performance, which has seen a decline of 3.02% as of December 31, 2024. This downturn follows a brief period of consecutive gains, suggesting a potential shift in market dynamics. On the latest trading day, Pfizer opened lower, experiencing a notable gap down of 2.47% and reaching an intraday low of Rs 5178.85, reflecting a decrease of 3.5%. Despite this recent performance dip, the stock continues to trade above its 5-day, 20-day, and 200-day moving averages, although it is currently lagging behind the 50-day and 100-day moving averages. In the context of broader market trends, Pfizer's one-day performance was notably weaker than the Sensex, which recorded a decline of 0.66%. Over the past month, Pfizer's stock has decreased by 1.99%, while the Sensex has experienced a slightly larger decline of 2.60%. Furthermore, Pfizer has been added to MarketsMOJO's list, indicating ongoing assessments of its market position and performance metrics.

Pfizer, a prominent player in the pharmaceuticals and drugs industry, has recently experienced a revision in its stock evaluation. The adjustment reflects the company's current market performance, which has shown a decline of 3.02% as of December 31, 2024. This downturn comes after a brief period of consecutive gains, indicating a potential trend reversal.
On the trading day, Pfizer opened lower, with a notable gap down of 2.47%, and reached an intraday low of Rs 5178.85, marking a decrease of 3.5%. Despite this recent performance, the stock remains above its 5-day, 20-day, and 200-day moving averages, although it is currently trailing behind the 50-day and 100-day moving averages.

In the broader market context, Pfizer's one-day performance lagged behind the Sensex, which recorded a decline of 0.66%. Over the past month, Pfizer's stock has decreased by 1.99%, while the Sensex has seen a slightly larger decline of 2.60%. Additionally, Pfizer has been added to MarketsMOJO's list, reflecting ongoing evaluations of its market position and performance indicators.